Figure 5From: Natalizumab treatment for multiple sclerosis: Middle East and North Africa regional recommendations for patient selection and monitoring Regional recommendations for using natalizumab in anti-JCV antibody-positive patients. B/R: Benefit/risk; IS: immunosuppression; JCV: John Cunningham virus.Back to article page